Profile
| Metric | Value |
|---|---|
| Full Name | Dyne Therapeutics, Inc. |
| Ticker | NASDAQ: DYN |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Country | United States |
| IPO | |
| Indexes | Not included |
| Website | dyne-tx.com |
| Employees | 206 |
Key Metrics
| Metric | Date | Value |
|---|---|---|
| Price | $17.35 | |
| Price, 1D Change | -2.36% | |
| Market Cap | $2B | |
| - | ||
| PE Ratio | - | |
| Beta | 1.69 | |
| Revenue | $0 | |
| Revenue, 1Y Change | 0.00% | |
| EPS | -$3.37 | |
| EPS, 1Y Change | +14.71% |
Chart
Add series to chart(max: 6)
Series
SUGGESTED SERIES
Events
| Metric | Date | Value |
|---|---|---|
| Next Earnings | ||
| Last Qtr. Earnings | ||
| Last Ann. Earnings | ||
| Last Ex-Dividend | N/A | N/A |
| Next Ex-Dividend | N/A | N/A |
| Last Split | N/A | N/A |
| Next Split | N/A | N/A |
| Last Ticker Change | N/A | N/A |
| Next Ticker Change | N/A | N/A |
🔒 Log In To Unlock Full Data
Estimates
| Metric | Date | Value |
|---|---|---|
| EPS | -$3.37 | |
| EPS Estimate | -$3.55 | |
| EPS Est. Change | -5.31% | |
| Revenue | $0.00 | |
| Revenue Estimate | - | |
| Revenue Est. Change | - | |
| Current Price | $17.35 | |
| Price Target | - | $39.50 |
| Price Tgt. Change | - | +127.67% |
🔒 Log In To Unlock Full Data
EPS
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| -$3.78 | -$3.95 | -4.58% | |
| -$3.45 | -$3.37 | +2.28% | |
| -$3.55 | N/A | -5.31% | |
| -$3.32 | N/A | +1.67% |
Revenue
| Year | Estimate | Reported | Surprise / Exp. |
|---|---|---|---|
| - | $0.00 | - | |
| - | $0.00 | - | |
| - | N/A | - | |
| - | N/A | - |
🔒 Log In To Unlock Full Data
Performance
| Metric | Date | Value |
|---|---|---|
| Price, 1Y | +9.33% | |
| Price, 3Y | +45.68% | |
| Market Cap, 1Y | +52.61% | |
| Market Cap, 3Y | +273.97% | |
| Revenue, 1Y | 0.00% | |
| Revenue, 3Y | 0.00% | |
| EPS, 1Y | +14.71% | |
| EPS, 3Y | -14.94% |
🔒 Log In To Unlock Full Data
Technical Indicators
| Metric | Date | Value |
|---|---|---|
| Current Price | $17.35 | |
| SMA 200 | $13.90 | |
| SMA 200 vs Price | -19.89% | |
| SMA 50 | $20.06 | |
| SMA 50 vs Price | +15.64% | |
| Beta | 1.69 | |
| ATR | $1.24 | |
| 14-Day RSI | 41.40 | |
| 10-Day Volatility | 58.09% | |
| 1-Year Volatility | 89.95% |
Dividends
| Metric | Date | Value |
|---|---|---|
| N/A | - | |
| Upcoming | N/A | N/A |
| - | ||
| - | ||
| Dividends Paid | $0.00 | |
| Payout Ratio | 0.00% |
🔒 Log In To Unlock Full Data
Income & Profitability
| Metric | Date | Value |
|---|---|---|
| Revenue | $0.00 | |
| EPS | -$3.37 | |
| Gross Profit | -$2.24M | |
| - | ||
| Operating Profit | -$343.89M | |
| - | ||
| Net Income | -$317.42M | |
| - | ||
| EBITDA | -$342.21M |
🔒 Log In To Unlock Full Data
Financial Health
| Metric | Date | Value |
|---|---|---|
| Debt To Equity | 0.04 | |
| Current Ratio | 15.60 | |
| Quick Ratio | 15.60 | |
| - | ||
| - | ||
| Altman Z-Score | 21.72 |
Valuations
| Metric | Date | Value |
|---|---|---|
| PE Ratio | - | |
| PS Ratio | - | |
| PB Ratio | 3.58 | |
| EV/EBITDA | -4.04 | |
| Enterprise Value | N/A | - |
Balance Sheet
| Metric | Date | Value |
|---|---|---|
| Book Value | $629.84M | |
| Cash & Equivalents | $435.45M | |
| Total Assets | $691.23M | |
| Current Assets | $659.28M | |
| Total Liabilities | $61.40M | |
| Current Liabilities | $42.26M | |
| Total Debt | $23.99M | |
| Short Term Debt | $4.85M | |
| Accounts Payable | $6.56M |
Expenses
| Metric | Date | Value |
|---|---|---|
| Total Expenses | $343.89M | |
| Operating Expenses | $343.89M | |
| Cost Of Goods Sold | $2.24M | |
| SG&A | $62.48M | |
| D&A | $1.67M | |
| Interest Expense | $0.00 | |
| Income Tax | $0.00 |
Cash Flow
| Metric | Date | Value |
|---|---|---|
| CFO | -$292.37M | |
| CFI | -$204.08M | |
| CFF | $809.90M | |
| Capex | $2.38M | |
| Free Cash Flow | -$294.75M |
Recent analyst updates
| Metric | Date | Value |
|---|---|---|
| Evercore ISI Group | → | |
| Stifel | → | |
| Oppenheimer | → | |
| Morgan Stanley | → | |
| Chardan Capital | → | |
| HC Wainwright & Co. | → | |
| JP Morgan | → | |
| Oppenheimer | → | |
| RBC Capital | → | |
| HC Wainwright & Co. | → |
Analyst sentiment
Institutional ownership
Screeners with DYN
Data Sources & References
- DYN Official Website www.dyne-tx.com
- Most Recent Quarterly Report (10-Q) www.sec.gov/Archives/edgar/data/1818794/000119312525266882/0001193125-25-266882-index.htm
- Most Recent Annual Report (10-K) www.sec.gov/Archives/edgar/data/1818794/000095017025028356/0000950170-25-028356-index.htm
- DYN Profile on Yahoo Finance finance.yahoo.com/quote/DYN
- DYN Profile on NASDAQ.com www.nasdaq.com/market-activity/stocks/dyn
FAQ
What is the ticker symbol for Dyne Therapeutics, Inc.?
The ticker symbol for Dyne Therapeutics, Inc. is NASDAQ:DYN
Does Dyne Therapeutics, Inc. pay dividends?
No, Dyne Therapeutics, Inc. does not pay dividends
What sector is Dyne Therapeutics, Inc. in?
Dyne Therapeutics, Inc. is in the Healthcare sector
What industry is Dyne Therapeutics, Inc. in?
Dyne Therapeutics, Inc. is in the Biotechnology industry
What country is Dyne Therapeutics, Inc. based in?
Dyne Therapeutics, Inc. is headquartered in United States
When did Dyne Therapeutics, Inc. go public?
Dyne Therapeutics, Inc. initial public offering (IPO) was on September 17, 2020
Is Dyne Therapeutics, Inc. in the S&P 500?
No, Dyne Therapeutics, Inc. is not included in the S&P 500 index
Is Dyne Therapeutics, Inc. in the NASDAQ 100?
No, Dyne Therapeutics, Inc. is not included in the NASDAQ 100 index
Is Dyne Therapeutics, Inc. in the Dow Jones?
No, Dyne Therapeutics, Inc. is not included in the Dow Jones index
When was Dyne Therapeutics, Inc. last earnings report?
Dyne Therapeutics, Inc.'s most recent earnings report was on November 5, 2025
When does Dyne Therapeutics, Inc. report earnings?
The next expected earnings date for Dyne Therapeutics, Inc. is February 26, 2026